The Journal of dermatological treatment最新文献_第7页

Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity. 用生物制剂治疗的小儿和青年牛皮癣患者的性别差异：不良事件和疾病活动性的差异

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-07-23 DOI: 10.1080/09546634.2025.2532672

Malak Al-Gawahiri, Liana Barenbrug, Ewald M Bronkhorst, Elke M G J de Jong, Juul M P A van den Reek, Marieke M B Seyger

{"title":"Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity.","authors":"Malak Al-Gawahiri, Liana Barenbrug, Ewald M Bronkhorst, Elke M G J de Jong, Juul M P A van den Reek, Marieke M B Seyger","doi":"10.1080/09546634.2025.2532672","DOIUrl":"https://doi.org/10.1080/09546634.2025.2532672","url":null,"abstract":"Introduction: Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.Methods: Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes.Results: We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.Conclusion: Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2532672"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the environmental impact of medication packaging in dermatology. 皮肤科药品包装对环境影响的评价。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-07-18 DOI: 10.1080/09546634.2025.2528719

Georgia Marquez-Grap, Andrea Leung, Payton Smith, Tina Bhutani

引用次数: 0

Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report. 刺猬通路抑制剂（HHI）联合放疗和免疫治疗晚期基底细胞癌1例报告

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-06 DOI: 10.1080/09546634.2025.2462783

Zhuren Ruan, Chen Zhao, Longshan Li, Xianghui Li, Zhijian Yao, Gao Wei

引用次数: 0

Intralesional triamcinolone for inflammatory acne: a comparative study of dose efficacy and investigation of a novel injection assistance device to enable self-administration of intralesional therapy. 局部注射曲安奈德治疗炎症性痤疮：剂量疗效的比较研究和一种新型注射辅助装置的研究，使局部治疗能够自我管理。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-05-28 DOI: 10.1080/09546634.2025.2504656

Lyra B Olson, Callie M Roberts, Sunil S Dhawan, Ann Mazor Reed, Eduardo Weiss, Martin Zaiac, Justin M Ko, Arash Mostaghimi

{"title":"Intralesional triamcinolone for inflammatory acne: a comparative study of dose efficacy and investigation of a novel injection assistance device to enable self-administration of intralesional therapy.","authors":"Lyra B Olson, Callie M Roberts, Sunil S Dhawan, Ann Mazor Reed, Eduardo Weiss, Martin Zaiac, Justin M Ko, Arash Mostaghimi","doi":"10.1080/09546634.2025.2504656","DOIUrl":"10.1080/09546634.2025.2504656","url":null,"abstract":"Background: Acne is the most common dermatologic condition in the U.S., but few treatments work for individual lesions. One effective spot treatment is an injection of low dose steroid into the inflammatory lesion by a dermatologist or other provider. However, this treatment is not readily available to most patients given limited access to timely in-office injections.Objective: First, to evaluate the safety and efficacy of intralesional triamcinolone injection for inflammatory acne delivered by via self-injection with a novel injection assistance device versus standard provider-delivered intralesional injection. Second, to compare efficacy and safety of intralesional triamcinolone acetonide at 0.1% versus 0.2%.Methods: Three sequentially enrolling, open label arms of study were performed across two clinical trials (NCT06170593, NCT06186596). The first two arms compared standard provider injections to device-assisted patient-administered injections of 0.1% triamcinolone into inflammatory acne lesions. A third arm was enrolled to compare efficacy of 0.1% vs. 0.2% triamcinolone delivered via self-injections as assessed by patient-reported outcomes.Results: Patient-administered injections showed comparable safety and efficacy to provider-administered injections. Patients with more severe lesions reported improved lesion resolution at the higher 0.2% triamcinolone dose. There were no adverse events in any group.Conclusion: This study supports the feasibility of self-administered, provider-prescribed intralesional treatments for inflammatory acne. Home administration could expedite lesion resolution and reduce scarring risk.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2504656"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fractional microneedle radiofrequency with the application of vitamin C, E, and ferulic acid serum for neck skin rejuvenation: a prospective, double-blinded, split-neck, placebo-controlled trial. 微针射频与维生素C， E和阿魏酸血清的应用颈部皮肤年轻化：一项前瞻性，双盲，裂颈，安慰剂对照试验。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2504655

Jemin Kim, Sang Gyu Lee, Jihee Boo, Hyun Kim, Shinwon Hwang, Chaocheng Liu, Xi Yan, Patricia Brieva, Jihee Kim

{"title":"Fractional microneedle radiofrequency with the application of vitamin C, E, and ferulic acid serum for neck skin rejuvenation: a prospective, double-blinded, split-neck, placebo-controlled trial.","authors":"Jemin Kim, Sang Gyu Lee, Jihee Boo, Hyun Kim, Shinwon Hwang, Chaocheng Liu, Xi Yan, Patricia Brieva, Jihee Kim","doi":"10.1080/09546634.2025.2504655","DOIUrl":"10.1080/09546634.2025.2504655","url":null,"abstract":"Purpose: To evaluate the efficacy of fractional microneedle radiofrequency (FMR) combined with topical antioxidant serum (vitamin C, E, and ferulic acid) compared to FMR alone for neck rejuvenation.Materials and methods: This prospective, randomized, double-blind, split-neck trial included 31 participants aged 30-65 years with visible signs of neck aging. Subjects underwent two FMR treatments at 4-week intervals. Immediately post-treatment, participants applied antioxidant serum to one randomly assigned side of the neck and placebo to the contralateral side daily. Efficacy was assessed by Fitzpatrick Wrinkle and Elastosis Scale, Global Esthetic Improvement Scale (GAIS), and biophysical skin parameters. Histological analyses evaluated elastin production and markers of senescence.Results: At week 12, the antioxidant-treated neck side showed significantly greater reductions in wrinkle severity (29.9% vs. 18.0%; p < 0.001), increased elasticity (12.9% vs. 2.3%; p < 0.001), and higher GAIS improvement (87.5% vs. 14.3%). Histologically, antioxidant-treated areas exhibited increased elastin and reduced cellular senescence markers (p16 and γ-H2A.X).Conclusions: Combining FMR with topical antioxidant serum substantially enhances neck skin rejuvenation, demonstrating superior clinical and histological outcomes. This approach effectively addresses neck aging, highlighting antioxidants as valuable adjunctive therapies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2504655"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis. 使用tapinarof乳膏治疗特应性皮炎或斑块型牛皮癣患者的毛囊事件和接触性皮炎的特点和管理。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-07-02 DOI: 10.1080/09546634.2025.2517388

Linda Stein Gold, Matthew J Bruno, G Michael Lewitt, Adelaide A Hebert

{"title":"Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.","authors":"Linda Stein Gold, Matthew J Bruno, G Michael Lewitt, Adelaide A Hebert","doi":"10.1080/09546634.2025.2517388","DOIUrl":"10.1080/09546634.2025.2517388","url":null,"abstract":"Purpose: Provide insights into the incidence, pre-sentation and management of follicular events and contact dermatitis in patients with plaque psoriasis or atopic dermatitis (AD) treated with tapinarof cream 1%.Materials and methods: Key clinical trial publications for tapinarof were reviewed and augmented with the authors' opinions based on real-world clinical experience.Results: In the PSOARING and ADORING trials, discontinuation rates due to follicular events and contact dermatitis were low and most patients did not require dose modifications or treatment interruptions. In our experience, which includes the use of tapinarof in combination with other agents, tapinarof is generally well tolerated and if events of folliculitis or contact dermatitis occur, patients can be advised to temporarily discontinue application on affected sites until the event resolves, continuing application to other affected areas and body regions. Education on the correct application of tapinarof is important in the management of psoriasis and AD.Conclusions: Tapinarof is a novel topical treatment option for adults with plaque psoriasis and patients with AD, with no restrictions regarding application sites and duration of use. Follicular events and contact dermatitis associated with tapinarof treatment are generally mild and self-limiting and rarely interfere with therapy.Clinicaltrials.gov numbers: NCT05014568, NCT05032859, NCT05142774, NCT03956355, NCT03983980, NCT04053387.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2517388"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spesolimab for a child with generalized pustular psoriasis accompanied epilepsy and hyperactivity. Spesolimab用于全身性脓疱性牛皮癣伴癫痫和多动症的儿童。

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-09-22 DOI: 10.1080/09546634.2025.2555210

Yudan Wang, Jie Qin, Li Peng, Linli He, Beichen Yang, Mei Yang, Yanyan Feng

引用次数: 0

Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report. 成功的guselkumab治疗牛皮癣患者经历肾上腺危机：一个案例报告。

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-08-26 DOI: 10.1080/09546634.2025.2545297

Nana Luo, Yi Shen, Luxin Su, Pingsheng Hao

{"title":"Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report.","authors":"Nana Luo, Yi Shen, Luxin Su, Pingsheng Hao","doi":"10.1080/09546634.2025.2545297","DOIUrl":"10.1080/09546634.2025.2545297","url":null,"abstract":"Purpose: Prolonged glucocorticoid therapy may lead to adrenal insufficiency (AI) or even adrenal crisis (AC) due to suppression of the hypothalamic-pituitary-adrenal (HPA) axis.Methods: This case report describes a male patient with psoriasis who had received long-term irregular glucocorticoid therapy for psoriasis management. Following an upper respiratory tract infection, the patient developed generalized skin lesions accompanied by systemic symptoms including abdominal pain, vomiting, fatigue, fever, and lethargy. After multiple misdiagnoses, the patient was ultimately diagnosed with psoriasis complicated by AC.Results: The patient was subjected to guselkumab combined with glucocorticoid therapy for the treatment of psoriasis and AC. After 6 months, complete resolution of skin lesions was achieved, and adrenal function returned to normal.Conclusions: Dermatologists should be aware of the potential for AI when prescribing glucocorticoids (topical or systemic) to treat psoriasis. Guselkumab represents a viable therapeutic option for psoriasis patients with concurrent AI/AC.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2545297"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

It is still a secret disease - clinical images in randomized controlled trials on hidradenitis suppurativa. 在化脓性汗腺炎的随机对照试验中，它仍然是一种神秘的疾病。

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-09-11 DOI: 10.1080/09546634.2025.2559004

Pernille Lindsø Andersen, Gregor Borut Jemec, Sam Polesie

{"title":"It is still a secret disease - clinical images in randomized controlled trials on hidradenitis suppurativa.","authors":"Pernille Lindsø Andersen, Gregor Borut Jemec, Sam Polesie","doi":"10.1080/09546634.2025.2559004","DOIUrl":"10.1080/09546634.2025.2559004","url":null,"abstract":"Purpose: Hidradenitis suppurativa (HS) is a recalcitrant, chronic, inflammatory skin disease characterized by painful nodules, abscesses, and tunnels, primarily affecting intertriginous areas. Despite its substantial negative impact on patients' quality of life, HS has been historically understudied. Recently, an increasing number of randomized controlled trials (RCTs) have expanded treatment options and informed clinical guidelines. While quantitative data using clinical scoring systems is standard to disseminate RCT results, this study aimed to assess the extent of clinical image dissemination, as this can increase transparency and support layperson communication.Materials and methods: A systematic review was performed on 265 identified articles, of which 37 met the inclusion criteria. Each trial was evaluated for the inclusion of clinical images and the number of patients represented.Results: Clinical images were included in 15 of 37 trials (40.5%), depicting only 33 of 4,327 randomized patients (0.7%) across 90 photos. Articles published before 2020 more frequently included photos than those published later (p = 0.008). The low inclusion rate of clinical photos in HS RCTs is, however, slightly higher than in comparable psoriasis and atopic dermatitis studies.Conclusions: Given dermatology's visual nature, the limited use of clinical photos in HS RCTs is notable. Increasing clinical photo dissemination in scientific articles may enhance research transparency, aid young physicians' education, and improve patient communication. However, standardized photo protocols and ethical considerations are essential for implementation.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2559004"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lessons from a decentralized trial in atopic dermatitis: promises and perils. 特应性皮炎分散试验的经验教训：希望与危险。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-03 DOI: 10.1080/09546634.2025.2480747

Zhihong Lai, Candice M Estes, Stephanie Lyke, Haq Nawaz

引用次数: 0